All subjects (n = 61) | MPA-ILD (n = 22) | Non-MPA-ILD (n = 39) | P value | |
---|---|---|---|---|
Age, mean ± SD | 75.1 ± 8.8 | 75.1 ± 9.2 | 75.2 ± 8.2 | 0.973 |
Male, N (%) | 31 (50.8%) | 9 (40.9%) | 22 (56.4%) | 0.293 |
Current or ex-smoker, N (%) | 35 (57.4%) | 11 (50.0%) | 24 (61.5%) | 0.428 |
BMI, kg/m2, mean ± SD | 22.1 ± 3.1 | 23.2 ± 3.3 | 21.5 ± 2.9 | 0.037 |
Acute exacerbation of ILD, N (%) | 9 (14.8%) | 1 (4.5%) | 8 (20.5%) | 0.138 |
Diffuse pulmonary hemorrhage, N (%) | 6 (9.8%) | 6 (27.3%) | 0 (0.0%) | < 0.001 |
KL-6 (U/mL), mean ± SD (available N = 56) | 913.9 ± 824.4 | 726.2 ± 594.3 | 1010.3 ± 913.0 | 0.225 |
SP-D (ng/mL), mean ± SD (available N = 40) | 151.9 ± 116.8 | 91.9 ± 76.8 | 169.3 ± 121.5 | 0.080 |
CRP (mg/dL), mean ± SD (available N = 61) | 1.8 ± 2.7 | 1.6 ± 2.5 | 2.1 ± 3.0 | 0.475 |
%FVC, mean ± SD (available N = 31) | 91.2 ± 19.1 | 98.3 ± 12.5 | 87.9 ± 21.0 | 0.160 |
FEV1/FVC ratio, % mean ± SD (available N = 31) | 77.3 ± 9.4 | 78.8 ± 9.8 | 76.5 ± 9.4 | 0.540 |
%DLCO, mean ± SD (available N = 29) | 81.5 ± 22.0 | 84.6 ± 15.5 | 79.9 ± 24.9 | 0.594 |
CPI, mean ± SD (available N = 29) | 27.7 ± 18.3 | 24.1 ± 13.1 | 29.6 ± 20.5 | 0.445 |
Anti-inflammatory agent (during follow-up), N (%) | 35 (57.4%) | 21 (95.5%) | 14 (35.9%) | < 0.001 |
Anti-fibrotic agent (during follow-up), N (%) | 4 (6.6%) | 0 (0.0%) | 4 (10.3%) | 0.287 |
Deaths (during follow-up), N (%) | 25 (41.0%) | 9 (40.9%) | 16 (41.0%) | > 0.999 |
Median follow-up, years (range) | 3.6 (0.1–11.9) | 3.2 (0.1–11.9) | 3.8 (0.2–11.7) | 0.376 |